Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating ABT-493 and ABT-530 with and without ribavirin in adults with hepatitis C who failed prior DAA therapy; completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493
• ABT-530
• Ribavirin (ribavirin)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-09-15